Bioactive Alginates and Obesity

生物活性藻酸盐与肥胖

基本信息

  • 批准号:
    BB/G00563X/1
  • 负责人:
  • 金额:
    $ 50.72万
  • 依托单位:
  • 依托单位国家:
    英国
  • 项目类别:
    Research Grant
  • 财政年份:
    2008
  • 资助国家:
    英国
  • 起止时间:
    2008 至 无数据
  • 项目状态:
    已结题

项目摘要

Obesity is one of the fastest growing medical issues across the western world and it is fast becoming one of the leading causes of mortality worldwide. At least one in thirteen annual deaths in the European Union are likely to be related to overweight. That is 337,000 deaths/year and Britain leads the E.U. table of deaths related to excess body weight. Half the adults in the U.K. are overweight and around one in four is obese. Obesity increases the risk of high blood pressure, heart disease and late onset diabetes with an estimated cost to the economy of £2 Billion/year. In general, women have a greater body mass index (BMI) distribution and higher obesity rate compared to men. Obesity is a condition associated with poverty and a poor diet in both the developed and developing nations. It is therefore particularly important that if treatment/prevention is delivered via diet that the foods should be affordable and acceptable e.g. bread, the vehicle we intend to trial. Because eating is a pleasurable experience and humans tend to over eat if food is available in excess, in particular high energy foods which are often rich in fat. Reducing fat metabolism and uptake is one approach to reducing weight gain. Therefore chemically synthesised inhibitors of the fat digesting enzymes, lipases are currently being used to treat obesity. At present the major lipase inhibitor available on prescription in the U.K. is orlistat (Xenical) which will reduce fat absorption by up to 30%. However side effects such as oily stools, flatulence and diarrhoea have meant reduced acceptability. Interestingly these side effects can be significantly reduced if the lipase inhibitor is taken with a dietary fibre supplement. Therefore a good solution would be a dietary fibre with lipase inhibitory activity. Alginate, a natural fibre from seaweed has these properties. We have demonstrated in our lab that alginates have a similar ability to inhibit lipase as orlistat. We therefore aim to screen a bank of alginates (over 20), some of which are already used in the food industry at low levels and other naturally occurring biopolymers to determine the best lipase inhibitor profile using a lab based colorimetric assay. Using the best inhibitors we will demonstrate their ability to inhibit lipase activity in conditions as close as possible to those in the gut, i.e. with other food components etc. The best candidate/s from the above studies will then be tested (delivered in bread in the first instance) in human volunteers. A group of healthy subjects will be used to determine acceptability of the biopolymer in the food vehicle and to determine the best balance between lipase inhibition and levels of biopolymer intake. Our preliminary studies showed no acceptability problems with alginate levels as high as 10% by weight in bread. Following the studies with the healthy subjects the biopolymer enriched foods will be tested to demonstrate calorific intake reduction in ileostomy patients. This study has the potential to provide evidence that normal foods supplemented with fibre biopolymers can be used to treat obesity/overweight and allow this to be translated by the food industry into the development of a range of other tasty and affordable food products. Such a range would have the potential to reduce calorific intake, as well as include the health benefits of dietary fibre.
肥胖是西方世界增长最快的医学问题之一,它正在迅速成为全球死亡的主要原因之一。欧盟每年至少有十三分之一的死亡可能与超重有关。这是每年337,000人死亡,英国领先欧盟。与超重有关的死亡表。英国一半的成年人超重,四分之一的人肥胖。肥胖会增加患高血压、心脏病和迟发性糖尿病的风险,估计每年给经济造成20亿英镑的损失。一般来说,与男性相比,女性的体重指数(BMI)分布更大,肥胖率更高。在发达国家和发展中国家,肥胖是一种与贫困和不良饮食有关的疾病。因此,特别重要的是,如果通过饮食提供治疗/预防,那么食物应该是负担得起的和可接受的,例如面包,我们打算试验的载体。因为吃是一种愉快的体验,如果食物过量,特别是富含脂肪的高能量食物,人类往往会吃得过多。减少脂肪代谢和吸收是减少体重增加的一种方法。因此,化学合成的脂肪消化酶抑制剂,脂肪酶目前被用于治疗肥胖症。目前,在英国处方上可用的主要脂肪酶抑制剂。是奥利司他(赛尼可),这将减少高达30%的脂肪吸收。然而,副作用,如油性粪便,肠胃气胀和腹泻意味着减少接受。有趣的是,如果脂肪酶抑制剂与膳食纤维补充剂一起服用,这些副作用可以显着减少。因此,具有脂肪酶抑制活性的膳食纤维将是一个很好的解决方案。海藻酸盐,一种来自海藻的天然纤维具有这些特性。我们已经在实验室中证明了藻酸盐具有与奥利司他相似的抑制脂肪酶的能力。因此,我们的目标是筛选一组藻酸盐(超过20种),其中一些已经在食品工业中以低水平使用,其他天然存在的生物聚合物使用基于实验室的比色测定来确定最佳脂肪酶抑制剂谱。使用最好的抑制剂,我们将证明它们在尽可能接近肠道条件下抑制脂肪酶活性的能力,即与其他食物成分等。然后将在人类志愿者中测试上述研究中的最佳候选物(首先在面包中提供)。将使用一组健康受试者来确定食品载体中生物聚合物的可接受性,并确定脂肪酶抑制和生物聚合物摄入水平之间的最佳平衡。我们的初步研究表明,面包中海藻酸盐含量高达10%(重量)没有可接受性问题。在对健康受试者进行研究后,将对富含生物聚合物的食物进行测试,以证明回肠造口术患者的热量摄入减少。这项研究有可能提供证据证明,补充纤维生物聚合物的正常食品可用于治疗肥胖/超重,并允许食品工业将其转化为一系列其他美味和负担得起的食品的开发。这样的范围将有可能减少热量摄入,并包括膳食纤维的健康益处。

项目成果

期刊论文数量(7)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Alginate as a protease inhibitor in vitro and in a model gut system; selective inhibition of pepsin but not trypsin.
  • DOI:
    10.1016/j.carbpol.2015.05.062
  • 发表时间:
    2015-10-20
  • 期刊:
  • 影响因子:
    11.2
  • 作者:
    Chater PI;Wilcox MD;Brownlee IA;Pearson JP
  • 通讯作者:
    Pearson JP
Biological activity of alginate and its effect on pancreatic lipase inhibition as a potential treatment for obesity.
藻酸盐的生物学活性及其对胰腺脂肪酶抑制作用的作用,作为肥胖症的潜在治疗方法。
  • DOI:
    10.1016/j.foodhyd.2015.02.019
  • 发表时间:
    2015-07
  • 期刊:
  • 影响因子:
    10.7
  • 作者:
    Houghton, David;Wilcox, Matthew D.;Chater, Peter I.;Brownlee, Iain A.;Seal, Chris J.;Pearson, Jeffrey P.
  • 通讯作者:
    Pearson, Jeffrey P.
The modulation of pancreatic lipase activity by alginates.
  • DOI:
    10.1016/j.foodchem.2013.09.075
  • 发表时间:
    2014-03-01
  • 期刊:
  • 影响因子:
    8.8
  • 作者:
    Wilcox, Matthew D.;Brownlee, Iain A.;Richardson, J. Craig;Dettmar, Peter W.;Pearson, Jeffrey P.
  • 通讯作者:
    Pearson, Jeffrey P.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jeff Pearson其他文献

Measurement of stainer bath and slide contamination in batch h&e stainers
  • DOI:
    10.1016/s0031-3025(16)32627-7
  • 发表时间:
    2012-01-01
  • 期刊:
  • 影响因子:
  • 作者:
    John B. Carpenter;Angie Cahill;Jeff Pearson
  • 通讯作者:
    Jeff Pearson

Jeff Pearson的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jeff Pearson', 18)}}的其他基金

Physiologically relevant modelling of the aerodigestive tract as a delivery and screening platform for drugs and bioactives
呼吸消化道的生理相关模型作为药物和生物活性物质的输送和筛选平台
  • 批准号:
    BB/R019657/1
  • 财政年份:
    2018
  • 资助金额:
    $ 50.72万
  • 项目类别:
    Research Grant
An integrated upper GI model of digestion and absorption - the commercial 'Holy Grail'
消化和吸收的综合上消化道模型 - 商业“圣杯”
  • 批准号:
    BB/N012666/1
  • 财政年份:
    2016
  • 资助金额:
    $ 50.72万
  • 项目类别:
    Research Grant
A physiologically relevant in vitro model gut system
生理相关的体外模型肠道系统
  • 批准号:
    BB/M005631/1
  • 财政年份:
    2014
  • 资助金额:
    $ 50.72万
  • 项目类别:
    Research Grant
Designing the most effective vehicle to deliver alginate to effectively reduce fat digestion and absorption
设计最有效的海藻酸盐输送载体,有效减少脂肪消化吸收
  • 批准号:
    BB/K020307/1
  • 财政年份:
    2013
  • 资助金额:
    $ 50.72万
  • 项目类别:
    Research Grant
Development of transgenic mice to determine the role of intelectins as effectors of gastrointestinal nematode expulsion
开发转基因小鼠以确定intelectin作为胃肠道线虫排出效应器的作用
  • 批准号:
    BB/E008593/1
  • 财政年份:
    2007
  • 资助金额:
    $ 50.72万
  • 项目类别:
    Research Grant

相似海外基金

Étude des interactions de sorption et de séquestration de polluants sur des alginates
海藻酸盐污染物吸附与封存相互作用研究
  • 批准号:
    571945-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 50.72万
  • 项目类别:
    University Undergraduate Student Research Awards
Engineering an Islet Thread from zwitterionically modified alginates for type 1 diabetes
利用两性离子改性藻酸盐设计胰岛丝,用于治疗 1 型糖尿病
  • 批准号:
    9910390
  • 财政年份:
    2018
  • 资助金额:
    $ 50.72万
  • 项目类别:
Engineering an Islet Thread from zwitterionically modified alginates for type 1 diabetes
利用两性离子改性藻酸盐设计胰岛丝,用于治疗 1 型糖尿病
  • 批准号:
    10402773
  • 财政年份:
    2018
  • 资助金额:
    $ 50.72万
  • 项目类别:
ALGIPRO - Alginates by Production Scale Fermentation and Epimerisation
ALGIPRO - 通过生产规模发酵和差向异构化生产海藻酸盐
  • 批准号:
    102148
  • 财政年份:
    2016
  • 资助金额:
    $ 50.72万
  • 项目类别:
    Collaborative R&D
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了